Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Leishen Energy Holding Co., Ltd. - Ordinary Shares (NQ:LSE)

12.50 +4.73 (+60.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Leishen Energy Holding Co., Ltd. - Ordinary Shares

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
65% oncology products revenue growth drove profitable operation and supported new ATTC platform 
From HUTCHMED (China) Limited
Via GlobeNewswire
Nexxen Expands U.S. Partnership with Tubi to U.K.
Strategic partnership enhances advertiser engagement and monetisation in the growing U.K. streaming market 
From Nexxen International Ltd.
Via GlobeNewswire
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Executive Appointments Strengthen Nexxen’s Data, Streaming and Omnichannel Expertise
Strategic leadership hires enhance the company’s U.S. regional and global growth as well as its commitment to clients 
From Nexxen International Ltd.
Via GlobeNewswire
Caledonia Mining Corporation Plc: Notice of Results and Investor Presentation
From Caledonia Mining Corporation Plc
Via GlobeNewswire
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments 
From AVACTA GROUP PLC
Via GlobeNewswire
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2024 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
Caledonia Mining Corporation Plc: Appointment of New Chief Financial Officer
From Caledonia Mining Corporation Plc
Via GlobeNewswire
Leishen Energy Holding Co., Ltd. Announces Fiscal Year 2024 Financial Results Highlighting Strong Operating Cash Flow and Stable Gross Margins
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire
Caledonia Mining Corporation Plc: Appointments of Stefan Buys and Lesley Goldwasser as Non-Executive Directors
From Caledonia Mining Corporation Plc
Via GlobeNewswire
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Metals & Mining Virtual Investor Conference Agenda Announced for February 12th and 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Nexxen Fuels Growth with Live Sports Offerings and Key Partnerships, Reaching Highly Engaged Audiences Across Channels
By collaborating with publisher partners and DSPs, Nexxen saw an increase in spend on live sports packages, including a 315% increase from StackAdapt campaigns 
From Nexxen International Ltd.
Via GlobeNewswire
Caledonia Mining Corporation Plc: Blanket Mine Q4 and FY 2024 Production and 2025 Guidance
Blanket production meets guidance; continued investment in growth and efficiency 
From Caledonia Mining Corporation Plc
Via GlobeNewswire
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
From HUTCHMED (China) Limited
Via GlobeNewswire
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Nexxen Launches Nexxen U, a First-of-its-Kind Education Program for Linear, Connected TV and Digital Convergence
From Nexxen International Ltd.
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
From HUTCHMED (China) Limited
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.